Second-Most Common Breast Cancer Subtype May Benefit From Personalized Treatment Approach, UPCI Finds
PITTSBURGH, Feb. 26, 2014
– The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by University of Pittsburgh Cancer Institute
Invasive lobular carcinoma, which is characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers that indicate there may be benefits from drug therapies beyond those typically prescribed for the more common invasive ductal carcinoma. The results will be published in the March 1 issue of the journal Cancer Research
Patients with invasive lobular carcinoma are typically treated through surgical removal of the cancer, followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive ductal carcinoma.
“However, recent analyses have shown that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma,” said senior author Steffi Oesterreich, Ph.D., professor at UPCI, a partner with UPMC CancerCenter
, and director of education at the Women’s Cancer Research Center
. “Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to a potential target for drug therapy in future clinical trials, which we are developing.”
The UPCI study, funded by the Breast Cancer Research Foundation
and the U.S. Department of Defense
, included collaborations across multiple disciplines, ranging from biostatistics and biomedical informatics to pathology and human genetics, in order to produce results with the potential for rapid translation into clinical therapies.
“In addition to its potential clinical implications, the study highlights the need for more and better models mimicking invasive lobular cancer that can be used for laboratory studies,” said lead author Matthew Sikora, Ph.D., a postdoctoral associate at UPCI.
“Because lobular carcinomas account for only 10 to 15 percent of breast cancers, while ductal carcinomas make up nearly 80 percent, lobular carcinomas are a less attractive option for laboratory study,” said Dr. Sikora. “However, 30,000 women in the U.S. are diagnosed with lobular carcinoma every year, so there is a great need for further study of this disease.”
Additional co-authors of this study include Kristine L. Cooper, M.S., Amir Bahreini, B.S., Soumya Luthra, M.S., Uma Chandran, Ph.D., M.S.I.S., Nancy E. Davidson, M.D., and David J. Dabbs, M.D., all of Pitt; and Guoying Wang, M.S., and Alana L. Welm, Ph.D., both of the University of Utah.
This research was supported by the Breast Cancer Research Foundation, Noreen Fraser Foundation, Department of Defense Breast Cancer Research Program fellowship and Era of Hope Scholar Award, and Pennsylvania Department of Health.